Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics

Schizophrenia Research

Volumn 145, Issue 1-3, 2013, Pages 116-119

  Suzuki, Yutaro ^a   Sugai, Takuro ^a   Fukui, Naoki ^a   Watanabe, Junzo ^a   Ono, Shin ^a   Tsuneyama, Nobuto ^a   Saito, Mami ^a   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Aripiprazole; Olanzapine; Perospirone; Quetiapine; Risperidone

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PEROSPIRONE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROLACTIN; REGRESSION ANALYSIS; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84875278312     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.12.027     Document Type: Article

References (19)

1. Bushe C., Sniadecki J., Bradley A.J., Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J. Psychopharmacol. 2010, 24(7):1001-1009.
2. Byerly M.J., Marcus R.N., Tran Q.V., Eudicone J.M., Whitehead R., Baker R.A. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr. Res. 2009, 107(2-3):218-222. (Epub 2008 Nov 26).
3. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 2000, 22(9):1085-1096.
4. de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr. Opin. Investig. Drugs 2002, 3:121-129.
5. Dickson R.A., Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 1999, 35:S75-S86. (Suppl.).
6. Fraguas D., Correll C.U., Merchán-Naranjo J., Rapado-Castro M., Parellada M., Moreno C., Arango C. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur. Neuropsychopharmacol. 2011, 21(8):621-645.
7. Hirose A., Kato T., Ohno Y., Shimizu H., Tanaka H., Nakamura M., Katsube J. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J. Pharmacol. 1990, 53:321-329.
8. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 2000, 57(6):553-559.
9. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999, 19:57-61.
10. Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., van den Bosch R.J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry 2005, 162:1010-1012.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223. (22).
12. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum. Psychopharmacol. 2010, 25(4):281-297.
13. Melkersson K.I. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. 2006, 21:529-532.
14. Onrust S.V., McClellan K. Perospirone. CNS Drugs 2001, 15:329-337.
15. Potkin S.G., Gharabawi G.M., Greenspan A.J., Mahmoud R., Kosik-Gonzalez C., Rupnow M.F., Bossie C.A., Davidson M., Burtea V., Zhu Y., Trivedi J.K.A. Double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr. Res. 2006, 85(1-3):254-265.
16. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry 2007, 164(9):1404-1410.
17. Suzuki Y., Fukui N., Watanabe J., Ono S., Sugai T., Tsuneyama N., Inoue Y., Someya T. Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(7):1266-1268.
18. Suzuki Y., Ono S., Sugai T., Fukui N., Watanabe J., Tsuneyama N., Sawamura K., Someya T. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum. Psychopharmacol. 2011, (Aug 5, Epub ahead of print). 10.1002/hup.1218.
19. Togo T., Iseki E., Shoji M., Oyama I., Kase A., Uchikado H., Katsuse O., Kosaka K. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J. Pharmacol. Sci. 2003, 91:259-262.